Biomolecules,
Journal Year:
2021,
Volume and Issue:
11(2), P. 195 - 195
Published: Jan. 30, 2021
There
are
currently
no
validated
biomarkers
which
can
be
used
to
accurately
diagnose
Alzheimer's
disease
(AD)
or
distinguish
it
from
other
dementia-causing
neuropathologies.
Moreover,
date,
only
symptomatic
treatments
exist
for
this
progressive
neurodegenerative
disorder.
In
the
search
new,
more
reliable
and
potential
therapeutic
options,
epigenetic
modifications
have
emerged
as
important
players
in
pathogenesis
of
AD.
The
aim
article
was
provide
a
brief
overview
current
knowledge
regarding
role
epigenetics
(including
mitoepigenetics)
AD,
possibility
applying
these
advances
future
AD
therapy.
Extensive
research
has
suggested
an
DNA
methylation
hydroxymethylation,
histone
posttranslational
modifications,
non-coding
RNA
regulation
(with
emphasis
on
microRNAs)
course
development
Recent
studies
also
indicated
mitochondrial
(mtDNA)
interesting
biomarker
since
dysfunctions
mitochondria
lower
mtDNA
copy
number
been
associated
with
pathophysiology.
evidence
suggests
that
changes
successfully
detected,
not
central
nervous
system,
but
cerebrospinal
fluid
periphery,
contributing
further
their
both
targets
Biosensors,
Journal Year:
2021,
Volume and Issue:
11(7), P. 214 - 214
Published: June 30, 2021
In
recent
years,
nanopore
technology
has
become
increasingly
important
in
the
field
of
life
science
and
biomedical
research.
By
embedding
a
nano-scale
hole
thin
membrane
measuring
electrochemical
signal,
can
be
used
to
investigate
nucleic
acids
other
biomacromolecules.
One
most
successful
applications
technology,
Oxford
Nanopore
Technology,
marks
beginning
fourth
generation
gene
sequencing
technology.
this
review,
operational
principle
for
signal
processing
are
documented.
Moreover,
review
focuses
on
using
including
diagnosis
cancer,
detection
viruses
microbes,
assembly
genomes.
These
show
that
is
promising
biological
sensing.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2022,
Volume and Issue:
41(1)
Published: March 15, 2022
DNA
methylation
is
one
of
the
most
important
epigenetic
mechanisms
to
regulate
gene
expression,
which
highly
dynamic
during
development
and
specifically
maintained
in
somatic
cells.
Aberrant
patterns
are
strongly
associated
with
human
diseases
including
cancer.
How
cell-specific
established
or
disturbed
a
pivotal
question
developmental
biology
cancer
epigenetics.
Currently,
compelling
evidence
has
emerged
that
long
non-coding
RNA
(lncRNA)
mediates
both
physiological
pathological
conditions.
In
this
review,
we
provide
an
overview
current
understanding
lncRNA-mediated
methylation,
emphasis
on
roles
mechanism
cancer,
best
our
knowledge,
not
been
systematically
summarized.
addition,
also
discuss
potential
clinical
applications
RNA-targeting
drug
development.
Biomolecules,
Journal Year:
2021,
Volume and Issue:
11(2), P. 195 - 195
Published: Jan. 30, 2021
There
are
currently
no
validated
biomarkers
which
can
be
used
to
accurately
diagnose
Alzheimer's
disease
(AD)
or
distinguish
it
from
other
dementia-causing
neuropathologies.
Moreover,
date,
only
symptomatic
treatments
exist
for
this
progressive
neurodegenerative
disorder.
In
the
search
new,
more
reliable
and
potential
therapeutic
options,
epigenetic
modifications
have
emerged
as
important
players
in
pathogenesis
of
AD.
The
aim
article
was
provide
a
brief
overview
current
knowledge
regarding
role
epigenetics
(including
mitoepigenetics)
AD,
possibility
applying
these
advances
future
AD
therapy.
Extensive
research
has
suggested
an
DNA
methylation
hydroxymethylation,
histone
posttranslational
modifications,
non-coding
RNA
regulation
(with
emphasis
on
microRNAs)
course
development
Recent
studies
also
indicated
mitochondrial
(mtDNA)
interesting
biomarker
since
dysfunctions
mitochondria
lower
mtDNA
copy
number
been
associated
with
pathophysiology.
evidence
suggests
that
changes
successfully
detected,
not
central
nervous
system,
but
cerebrospinal
fluid
periphery,
contributing
further
their
both
targets
